Search
Oramed Pharmaceuticals Inc
ORMPAdd to Watchlist
4.640USD
-0.090-1.90%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
187.67MMarket Cap
3.00P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-1.90%
5 Days
+13.45%
1 Month
+19.59%
6 Months
+112.70%
Year to Date
+74.64%
1 Year
+115.81%
TradingKey Stock Score of Oramed Pharmaceuticals Inc
Currency: USD Updated: 2026-05-15Key Insights
Oramed Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 173 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 6.25.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Oramed Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Oramed Pharmaceuticals Inc Highlights
StrengthsRisks
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 49.25% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.00M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.00M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 3.00, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.39M shares, increasing 12.86% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 147.50K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
6.250
Target Price
+34.70%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Oramed Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Oramed Pharmaceuticals Inc Info
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Ticker SymbolORMP
CompanyOramed Pharmaceuticals Inc
CEOKidron (Nadav)
Websitehttps://oramed.com/
Related Instruments
-0.03%
-1.75%
-0.15%
-1.11%
-1.77%
-1.79%
-2.22%
-1.88%
-2.35%
-1.63%
+0.43%
-2.99%
-0.37%
-1.64%
+1.79%
0.00%
-2.05%
-0.15%
-2.77%
+0.41%Popular Instruments
103.026
+0.866 (+0.85%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4539.770
+1.060 (+0.02%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
76991.710
-1255.650 (-1.60%)
422.240
-21.060 (-4.75%)
